Skip to main content

Clinical Trials Using Nivolumab

Review the clinical trials studying nivolumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 193

mFOLFIRINOX versus mFOLFOX with or without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Status: Active
Location: 682 locations
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Status: Active
Location: 656 locations
Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Status: Active
Location: 455 locations
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 441 locations
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 367 locations
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Status: Active
Location: 362 locations
Comparing Impact of Treatment Before or After Surgery in Patients with Stage II-IIIB Resectable Non-small Cell Lung Cancer
Status: Active
Location: 340 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 273 locations
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) versus Standard of Care (Lomustine) for the Treatment of Patients with Recurrent Glioblastoma
Status: Active
Location: 255 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 476 locations
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients with Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Status: Active
Location: 205 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 196 locations
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative
Status: Active
Location: 154 locations
Using Nivolumab Alone or with Cabozantinib to Prevent Mucosal Melanoma Return after Surgery
Status: Active
Location: 132 locations
Testing the Value of Adding Surgery after the Usual Treatment (Immunotherapy) for Patients with Pleural Mesothelioma
Status: Active
Location: 126 locations
Testing Nivolumab with or without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Status: Active
Location: 117 locations
Testing Nivolumab and Ipilimumab Immunotherapy with or without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Status: Active
Location: 91 locations
A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Status: Active
Location: 70 locations
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy after Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Status: Active
Location: 71 locations
Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Status: Active
Location: 42 locations
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Status: Active
Location: 48 locations
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Status: Active
Location: 28 locations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Status: Active
Location: 27 locations
Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Status: Active
Location: 25 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 24 locations